Rilotumumab
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for Rilotumumab, covering 2015-07-20 to 2020-03-19. Get the full timeline:
Most recent: Clinical Trial Update: Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches [Phase 2, Phase 3]